|
DE102014206881A1
|
|
Process for the purification of natural cytotoxic IgM antibodies
|
|
EP2602264A1
|
|
GDF-5 mutant for inducing cartilage formation
|
|
EP2537538A1
|
|
Bioresorbable Wound Dressing
|
|
EP2019117A1
|
|
Optimized purification process of recombinant growth factor protein
|
|
EP1915986A1
|
|
Lipid growth factor formulations
|
|
EP1880731A1
|
|
Human growth and differentiation factor GDF-5
|
|
EP1721909A1
|
|
Growth factor mutants with altered biological attributes
|
|
EP1698691A1
|
|
Growth factor mutants with improved biological activity
|
|
CA2519174A1
|
|
Improved osteoinductive materials
|
|
AU2002257703A1
|
|
Use of cytokines of the tgf-beta superfamily for the treatment and diagnosis of skin related disorders
|
|
EP1223966A2
|
|
Use of gdnf for treating corneal defects
|
|
US7025959B1
|
|
MP121, a growth/differentiation factor of the TGF-β family
|
|
WO0077195A1
|
|
Nucleic acid encoding novel egf-like growth factors
|
|
CA2372119A1
|
|
Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
|
|
US7067637B1
|
|
Antibody or antibody fragments specific for a protein of the TGF-β family
|
|
CA2342208A1
|
|
Use of tgf-beta inhibitors for treating cerebral disorders
|
|
US6764994B1
|
|
Growth/differential factor of the TGF-B family
|
|
US6171584B1
|
|
Method of treatment with growth/differentiation factors of the TGF-β family
|
|
EP0874052A2
|
|
Nucleic acid encoding a human protein phosphatase
|
|
HU0002386A3
|
|
Freeze-dried composition of bone morphogenetic protein human mp52
|
